Antibody Ingredients TRIZ Cases

Anti-FcRn antibodies bind human neonatal Fc receptors to facilitate targeted autoantibody removal.

Fc region engineering extends serum half-life, reducing administration frequency while improving treatment efficacy.

Novel anti-PD-1 monoclonal antibody with optimized complementarity determining regions enhances binding affinity to human PD-1 receptors.

A modified anti-glypican-3 antibody with specific amino acid substitutions in the Fc region enhances cytotoxicity.

Targeting the DDR1 stalk domain resolves monotherapy limitations by suppressing proliferation and inhibiting phosphorylation without combination agents.

MD-3 antibody binds ICAM-1 domain 2 to modulate dendritic cells, inducing antigen-specific T cell tolerance while reducing infection susceptibility.

An 8B6 antibody binds to O-acetylated GD2 ganglioside on cancer stem cells to trigger direct cytotoxicity and immune-mediated destruction.

Local quality engineering creates differential affinity that eliminates leukemia without causing immune dysfunction.

Anti-VISTA antibody inhibits VISTA to overcome PD-1 resistance.

Enzyme-cleavable linkers release antibodies in the tumor microenvironment, reducing systemic side effects.

Antibodies bind TEM7R on tumor endothelial cells to inhibit angiogenesis, resolving the trade-off between targeting specificity and therapeutic effectiveness.

A swallowable capsule delivers PCSK9 antibodies directly into the intestinal wall using pH-sensitive coatings and tissue-penetrating members.

Measuring CD73 expression levels in glioblastoma samples predicts patient response to immune checkpoint blockade, reducing severe toxicities.

Affinity maturation and defucosylation enhance 3C12 antibody specificity for CD83, resolving limited efficacy in graft-versus-host disease therapy.

Optimized CDR sequences in humanized antibodies achieve picomolar affinity against CSF-1R, resolving inadequate signaling inhibition in cancer therapies.

Amino acid substitutions in immunoglobulin domains reduce aggregation propensity while maintaining antigen binding activity.

Combining PD-1 or PD-L1 inhibitors with TIM-3, LAG-3, or CTLA-4 blockers targets multiple immune pathways simultaneously.

Amino acid substitutions in antibody constant regions reduce heterogeneity and improve pharmacokinetics by preventing disulfide bond differences.

Modify ISV C-termini with alanine to reduce aspecific protein interference, ensuring accurate anti-drug antibody detection.

IgA antibodies bind myeloid IgA receptors to stimulate neutrophil-mediated tumor cell killing while blocking CD47-SIRPα immune inhibition.

Monoclonal antibodies bind marinobufagenin, reducing blood pressure and cardiac hypertrophy in hypertension treatment.

Antibodies bind the extracellular domain of NBCn1 to block bicarbonate transport.

Targeting KLRG1 on pathogenic T cells enables selective depletion while preserving immune checkpoint inhibition and reducing autoimmune flares.

Conditional bispecific antibodies confine TGFβ inhibition to specific cell types, minimizing systemic toxicities.

Engineered antibodies optimize binding affinity and biophysical stability to overcome cancer immunosuppression.

Antibody targeting HSP90 beta reduces cancer cell migration, addressing limited understanding of novel tumor antigens.

Monoclonal antibodies bind soluble MICA/B proteins, reducing circulating levels that suppress immune activation in hepatocellular carcinoma.

Bispecific antibodies bridge GUCY2C-positive tumor cells and CD3 on T cells, resolving off-target toxicity while enhancing therapeutic precision.

Monoclonal antibodies with optimized complementarity determining region sequences bind Toll-like Receptor 7 targets.

Purified liquid hyperimmune globulin compositions with standardized IgG and IgM titers resolve antibody variability and transfusion risks in COVID-19 treatment.

Cell-free translation embeds target proteins into membrane vesicles, bypassing purification steps that cause misfolding and aggregation.

Quantitative immunofluorescence measures T-lymphocyte activation and proliferation markers in tumor tissue samples.

Engineered humanized antibodies bind glycosylated and non-glycosylated CD47 with optimized dissociation kinetics, resolving affinity-versus-toxicity trade-offs.

Anti-NRP1 antibody binds neuropilin 1 receptors with high affinity using phage display to inhibit cancer cell migration and neovascularization.

Anti-matriptase antibody immunoconjugates deliver cytotoxic agents to tumor cells via specific antigen binding.

Antibodies targeting de-N-acetylated polySia resolve cross-reactivity with normal tissues by exploiting local chemical modifications unique to tumor surfaces.

Combining a third-generation EGFR tyrosine kinase inhibitor with a bispecific antibody targeting EGFR and cMET overcomes treatment resistance in oncology.

Domain 2-binding LAG-3 agonists suppress T-cell proliferation via selective immunosuppression, avoiding adverse events from non-specific depletion.

Merging PD-1 and VEGFR-2 antagonists addresses immune evasion and angiogenesis, improving efficacy against metastatic lesions.

Humanized monoclonal antibody CT-011 modulates immune response alongside chemotherapeutic agents to inhibit tumor growth.

Specific IgG2 Fc mutations abolish Fc gamma receptor binding while preserving FcRn affinity, eliminating unwanted immune effector functions and tissue damage.

Removing light chains from conventional antibodies eliminates off-target binding while maintaining high affinity for BCMA.

Reducing fucose content in the Fc region boosts ADCC activity while excipients prevent aggregation at high concentrations.

Pre-formed human monoclonal antibodies block Bet v 1 binding to IgE on mast cells, preventing histamine release and avoiding lengthy desensitization therapy.

Antibody targeting CAPRIN-1 polypeptide damages cancer cells while sparing normal tissue to reduce adverse reactions.

5D5 antibodies bind circumsporozoite protein epitopes near protease cleavage sites, blocking Plasmodium sporozoite liver invasion.